![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cobra Bio-Man. | LSE:CBF | London | Ordinary Share | GB0031704835 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCBF RNS Number : 3115C Cobra Bio-Manufacturing PLC 11 November 2009 Cobra Biomanufacturing Plc ("Cobra" or the "Company") Possible Offer The Board of Cobra announces that it is in discussions which may or may not lead to an offer being made for the Company. The talks still remain at a preliminary stage and it is therefore too early to say whether the talks will result in an offer for the Company or, in the event that one is made, on what terms. This statement is made without the agreement or the approval of the potential offeror. A further announcement will be made when appropriate. In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, Cobra confirms that it currently has in issue 44,339,170 ordinary shares of 1p each, (no shares are held in treasury) and admitted to trading on AIM, a market operated by the London Stock Exchange. The International Securities Identification Number for Cobra's ordinary shares is GB0031704835. For further information, please contact: +-----------------------------------------+------------------------------+ | Cobra Biomanufacturing Plc | Tel: +44 (0) 1782 714 181 | +-----------------------------------------+------------------------------+ | Danny Chapchal, Chairman | | +-----------------------------------------+------------------------------+ | Simon Saxby, Chief Executive | | +-----------------------------------------+------------------------------+ | Peter Coleman, CFO and Company | | | Secretary | | +-----------------------------------------+------------------------------+ | | | +-----------------------------------------+------------------------------+ | Buchanan Communications | Tel: +44 (0) 207 466 5000 | +-----------------------------------------+------------------------------+ | Tim Anderson | | +-----------------------------------------+------------------------------+ | | | +-----------------------------------------+------------------------------+ | Seymour Pierce Ltd | Tel: +44 (0) 207 107 8000 | +-----------------------------------------+------------------------------+ | Chris Howard / Christopher Wren | | +-----------------------------------------+------------------------------+ The Directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the Directors of the Company (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to impact the import of this announcement. Seymour Pierce Limited ("Seymour Pierce"), which is regulated in the United Kingdom by the Financial Services Authority, is acting for Cobra in relation to the matters described in this announcement and is not advising any other person, and accordingly will not be responsible to anyone other than Cobra for providing the protections afforded to customers of Seymour Pierce or for providing advice in relation to the matters described in this announcement. Dealing Disclosure Requirements Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Cobra, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Cobra, they will be deemed to be a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of Cobra by Cobra, or by any of its respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk. "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel. This information is provided by RNS The company news service from the London Stock Exchange END OFDFFUFASSUSEDF
1 Year Cobra Bio-manufacturing Chart |
1 Month Cobra Bio-manufacturing Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions